Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Egenod

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Revue Des Maladies Respiratoires|September 8, 2023
[Bronchoscopic COPD treatments]T Egenod, G Deslee, B Degano
Revue Des Maladies Respiratoires|May 15, 2022
[The rise of interventional pulmonology: A special issue coordinated by the GETIF]N Guibert, H Dutau, B Escarguel, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Revue Des Maladies Respiratoires|September 8, 2023
[Bronchoscopic COPD treatments]T Egenod, G Deslee, B Degano
Revue Des Maladies Respiratoires|May 15, 2022
[The rise of interventional pulmonology: A special issue coordinated by the GETIF]N Guibert, H Dutau, B Escarguel, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.
Pageof 1